title: PET versus PET/CT dual-modality imaging in evaluation of lung cancer.
abstract: Non-small cell lung cancer (NSCLC) accounts for approximately 80% of bronchogenic malignancies. The choice of therapy options, including surgery, radiation therapy, and chemotherapy-used alone or in combination-is based on the tumor stage. Consequently, the accurate determination of tumor size, potential infiltration of adjacent structures, mediastinal lymph node involvement, and the detection of distant metastases are of central importance. The purpose of this article is to summarize the accuracy of dual-modality FDG-PET/CT imaging in staging of NSCLC as compared with FDG-PET alone, and with FDG-PET as well as CT read side by side. Furthermore, an optimized PET/CT protocol for patients who have lung cancer is outlined.
authors: Department of Nuclear Medicine, University of Duisburg, Hufelandstrasse 55 D-45122, Essen, Germany. lutz.freudenberg@uni-essen.de
authors: Lutz S
authors: LS
authors: Freudenberg
authors: Sandra J
authors: SJ
authors: Rosenbaum
authors: Thomas
authors: T
authors: Beyer
authors: Andreas
authors: A
authors: Bockisch
authors: Gerald
authors: G
authors: Antoch
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000473:pathology; D003287:Contrast Media; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18